Search Results - "Zapas, John L."

Seven-Year Follow-Up Assessment of Cardiac Function in NSABP B-31, a Randomized Trial Comparing Doxorubicin and Cyclophosphamide Followed by Paclitaxel (ACP) With ACP Plus Trastuzumab As Adjuvant Therapy for Patients With Node-Positive, Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer by ROMOND, Edward H, JEONG, Jong-Hyeon, FLYNN, Patrick J, ZAPAS, John L, POLIKOFF, Jonathan, GROSS, Howard M, BIGGS, David D, ATKINS, James N, TAN-CHIU, Elizabeth, PING ZHENG, YOTHERS, Greg, MAMOUNAS, Eleftherios P, RASTOGI, Priya, WOLMARK, Norman, SWAIN, Sandra M, GEYER, Charles E, EWER, Michael S, RATHI, Vikas, FEHRENBACHER, Louis, BRUFSKY, Adam, AZAR, Catherine A

“…Cardiac dysfunction (CD) is a recognized risk associated with the addition of trastuzumab to adjuvant chemotherapy for human epidermal growth factor receptor…”
Get full text

Definitive Results of a Phase III Adjuvant Trial Comparing Three Chemotherapy Regimens in Women With Operable, Node-Positive Breast Cancer: The NSABP B-38 Trial by SWAIN, Sandra M, GONG TANG, BRUFSKY, Adam M, BIGGS, David D, LEVINE, Edward A, ZAPAS, John L, PROVENCHER, Louise, NORTHFELT, Donald W, PAIK, Soonmyung, COSTANTINO, Joseph P, MAMOUNAS, Eleftherios P, WOLMARK, Norman, GEYER, Charles E, RASTOGI, Priya, ATKINS, James N, DONNELLAN, Paul P, FEHRENBACHER, Louis, AZAR, Catherine A, ROBIDOUX, André, POLIKOFF, Jonathan A

“…Anthracycline- and taxane-based three-drug chemotherapy regimens have proven benefit as adjuvant therapy for early-stage breast cancer. This trial (NSABP B-38;…”
Get full text

Oxaliplatin Combined With Weekly Bolus Fluorouracil and Leucovorin As Surgical Adjuvant Chemotherapy for Stage II and III Colon Cancer: Results From NSABP C-07 by KUEBLER, J. Philip, WIEAND, H. Samuel, ZAPAS, John L, GOODWIN, J. Wendall, FEHRENBACHER, Louis, RAMANATHAN, Ramesh K, CONLEY, Barbara A, FLYNN, Patrick J, SOORI, Gamini, COLMAN, Lauren K, LEVINE, Edward A, LANIER, Keith S, OCONNELL, Michael J, WOLMARK, Norman, SMITH, Roy E, COLANGELO, Linda H, YOTHERS, Greg, PETRELLI, Nicholas J, FINDLAY, Michael P, SEAY, Thomas E, ATKINS, James N

“…This phase III clinical trial evaluated the impact on disease-free survival (DFS) of adding oxaliplatin to bolus weekly fluorouracil (FU) combined with…”
Get full text

Clinical Impact of a Value-Based Decision: A Surgical Case Study by Kirkpatrick, John R., MD, MBA, FACS, Smith, Bruce M., MD, FACS, Zapas, John L., MD, FACS, Thomas, William L., MD, FACP

“…Background Value is an economic utility defined by quality and cost, with the maximum benefit achieved by improving quality and reducing cost simultaneously…”
Get full text

Long-Term Follow-Up of Cardiac Function and Quality of Life for Patients in NSABP Protocol B-31/NRG Oncology: A Randomized Trial Comparing the Safety and Efficacy of Doxorubicin and Cyclophosphamide (AC) Followed by Paclitaxel With AC Followed by Paclitaxel and Trastuzumab in Patients With Node-Positive Breast Cancer With Tumors Overexpressing Human Epidermal Growth Factor Receptor 2 by Ganz, Patricia A, Romond, Edward H, Cecchini, Reena S, Rastogi, Priya, Geyer, Jr, Charles E, Swain, Sandra M, Jeong, Jong-Hyeon, Fehrenbacher, Louis, Gross, Howard M, Brufsky, Adam M, Flynn, Patrick J, Wahl, Tanya A, Seay, Thomas E, Wade, 3rd, James L, Biggs, David D, Atkins, James N, Polikoff, Jonathan, Zapas, John L, Mamounas, Eleftherios P, Wolmark, Norman

“…Purpose Early cardiac toxicity is a risk associated with adjuvant chemotherapy plus trastuzumab. However, objective measures of cardiac function and…”
Get full text

Clonal dominance of CD133+ subset population as risk factor in tumor progression and disease recurrence of human cutaneous melanoma by SHARMA, BHUVNESH K, MANGLIK, V, O'CONNELL, MICHAEL, WEERARATNA, ASHANI, McCARRON, EDWARD C, BROUSSARD, JENNIFER N, DiVITO, KYLE A, SIMBULAN-ROSENTHAL, CYNTHIA M, ROSENTHAL, DEAN S, ZAPAS, JOHN L

“…Chemotherapeutic refractoriness of advanced cutaneous melanoma may be linked with melanoma-initiating cells, also known as melanoma stem cells. This study…”
Get full text

Diminished dose minimally invasive radioguided parathyroidectomy: a case for radioguidance by You, Christopher J, Zapas, John L

“…Minimally invasive radioguided parathyroidectomy (MIRP) has been established as an alternative to bilateral neck exploration (BNE) for primary…”
Get more information

Sequential administration of GM-CSF (Sargramostim) and IL-2 +/- autologous vaccine as adjuvant therapy in cutaneous melanoma: an interim report of a phase II clinical trial by Elias, E George, Zapas, John L, McCarron, Edward C, Beam, Sandra L, Hasskamp, Joanne H, Culpepper, W Joel

“…Granulocyte-macrophage colony-stimulating factor (GM-CSF) and interleukin-2 (IL-2) are 2 cytokines with distinct mechanisms of action that complement one…”
Get more information

In vivo effects of sequential granulocyte-macrophage colony stimulating factor (GM-CSF) and interleukin-2 (IL-2) on circulating dendritic cells (DC) in patients with surgically resected high risk cutaneous melanoma by Hasskamp, Joanne H, Elias, E George, Zapas, John L

“…Dendritic cells were assayed repeatedly in the peripheral blood of consenting melanoma patients receiving adjuvant biotherapy for high risk (stages IIb-IV)…”
Get full text

The risk of regional lymph node metastases in patients with melanoma less than 1.0 mm thick: recommendations for sentinel lymph node biopsy by Zapas, John L, Coley, H Christopher, Beam, Sandra L, Brown, Sally D, Jablonski, Kathleen A, Elias, E George

“…Lymphatic mapping and sentinel lymph node biopsy can upstage patients with intermediate thickness (1.0 to 4.0 mm) melanoma. Currently, there are no strict…”
Get full text

Perioperative adjuvant biotherapy in high-risk resected cutaneous melanoma: the results of 5 years of follow-up by Elias, Elias George, Zapas, John L, Beam, Sandra L, Culpepper, William J

“…A feasibility study was conducted to establish the safety and, to some extent, the effectiveness of a new approach of perioperative adjuvant biotherapy in…”
Get full text

GM-CSF and IL-2 combination as adjuvant therapy in cutaneous melanoma: early results of a phase II clinical trial by Elias, E George, Zapas, John L, Beam, Sandra L, Brown, Sally D

“…Cytokines have been used in the treatment of patients with cutaneous melanoma. Granulocyte-macrophage colony-stimulating factor (GM-CSF, sargramostim…”
Get more information

Abstract 4224: CD133 knockdown sensitizes melanoma to kinase inhibitors by AbdusSamad, Maryam, Gaur, Anirudh, Zhou, Hengbo, Zapas, John L., Simbulan-Rosenthal, Cynthia M., McCarron, Edward C., Rosenthal, Dean S.

“…Melanoma is an aggressive and lethal form of cancer, responsible for 9,710 deaths in the US every year, as indicated by the Surveillance Epidemiology and End…”
Get full text

Abstract 3891: CD133 is associated with resistance of melanoma to multikinase inhibition by Zhou, Hengbo, Abdussamad, Maryam, Alomari, Amani, Gaur, Anirudh, Rosenthal, Cynthia S., Zapas, John L., Rosenthal, Dean S.

“…Purpose: High-risk melanoma is a lethal cancer with a high recurrence rates and variable disease-free intervals, due to tumorigenic cell populations that are…”
Get full text

Abstract 1097: Immunohistochemical expression of growth factor receptors in different stages of human cutaneous melanoma by Sharma, Bhuvnesh K., Manglik, V, Hatfield, Glen, Broussard, Jennifer N., McCarron, Edward C., Zapas, John L.

“…Background: Melanoma is an aggressive and chemoresistant tumor.High risk melanoma is minimally susceptible to current treatment strategies.These treatment…”
Get full text

Abstract 3349: Immunoexpression of human melanoma stem markers during progressive stages of the disease by Sharma, Bhuvnesh K., Hasskamp, Joanne H., Manglik, Vinod, Zapas, John L., Elias, Elias George

“…Introduction: Human Cutaneous melanoma is known as potentially lethal malignancy due to its inherent intrinsic resistance to various cancer therapeutic…”
Get full text

Abstract 1921: Nonadherent human melanoma cell lines from lymph node metastases coexpress B cell markers and melanoma antigens by Hasskamp, Joanne H., Sharma, Bhuvnesh K., Zapas, John L., Elias, Elias George

“…Introduction Some atypical human melanoma cell lines are nonadherent to plastic culture flasks for unknown reasons. We have identified five nonadherent human…”
Get full text

NSABP B-38: Definitive analysis of a randomized adjuvant trial comparing dose-dense (DD) AC→paclitaxel (P) plus gemcitabine (G) with DD AC→P and with docetaxel, doxorubicin, and cyclophosphamide (TAC) in women with operable, node-positive breast cancer by Swain, Sandra M., Tang, Gong, Geyer, Charles E., Rastogi, Priya, Atkins, James Norman, Donnellan, Paul P., Fehrenbacher, Louis, Azar, Catherine A., Robidoux, Andre, Polikoff, Jonathan, Brufsky, Adam, Biggs, David D., Levine, Edward A., Zapas, John L., Provencher, Louise, Perez, Edith A., Paik, Soonmyung, Costantino, Joseph P., Mamounas, Eleftherios P., Wolmark, Norman

“…Abstract only LBA1000 Background: The primary aims were to determine whether adjuvant DD AC→PG will be superior to DD AC→P as well as to TAC in DFS and to…”
Get full text

NSABP B-38: Definitive analysis of a randomized adjuvant trial comparing dose-dense (DD) AC followed by paclitaxel (P) plus gemcitabine (G) with DD AC followed by P and with docetaxel, doxorubicin, and cyclophosphamide (TAC) in women with operable, node-positive breast cancer by Swain, Sandra M., Tang, Gong, Geyer, Charles E., Rastogi, Priya, Atkins, James Norman, Donnellan, Paul P., Fehrenbacher, Louis, Azar, Catherine A., Robidoux, Andre, Polikoff, Jonathan, Brufsky, Adam, Biggs, David D., Levine, Edward A., Zapas, John L., Provencher, Louise, Perez, Edith A., Paik, Soonmyung, Costantino, Joseph P., Mamounas, Eleftherios P., Wolmark, Norman

“…Abstract only LBA1000 The full, final text of this abstract will be available at abstract.asco.org at 12:01 AM (EDT) on Monday, June 4, 2012, and in the Annual…”
Get full text

In vivo effects of sequential granulocyte-macrophage colony stimulating factor (GM-CSF) and interleukin-2 (IL-2) on depressed peripheral blood dendritic cell (DC) counts in patients with stage IIB–IV melanoma by Zapas, John L., Hasskamp, Joanne, Beam, Sandra, Brown, Sally, Elias, E.George

“…Introduction: While leukocytosis is common during GM-CSF therapy for melanoma, it is unknown whether this translates to increases in circulating DC…”
Get full text